Seres Therapeutics, Inc. (MCRB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q3 '23: 127.2M Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 351K Q4 '25: 789K Q1 '26: 1.1M Q2 '26: 1.9M Q3 '23 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '24: -129.5M Q4 '24: -121.3M Q1 '25: -114.1M Q2 '25: -110.1M Q3 '25: -103.4M Q4 '25: -94M Q1 '26: -87.6M Q2 '26: -84M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-60M -30M 0 30M 60M 90M Q3 '24: -25.5M Q4 '24: 136K Q1 '25: 73M Q2 '25: 86M Q3 '25: 5.4M Q4 '25: 5.7M Q1 '26: -46.9M Q2 '26: -22.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '24: -157.2M Q4 '24: -148.6M Q1 '25: -86.5M Q2 '25: -59.9M Q3 '25: -23.1M Q4 '25: 1.1M Q1 '26: -42.2M Q2 '26: -51.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '24: -158.4M Q4 '24: -149M Q1 '25: -86.8M Q2 '25: -60.4M Q3 '25: -23.4M Q4 '25: 865K Q1 '26: -42.4M Q2 '26: -51.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 3.5M 7M 10.5M Q1 '24: 7.3M Q2 '24: 7.6M Q3 '24: 7.6M Q1 '25: 8.7M Q2 '25: 8.7M Q3 '25: 8.8M Q1 '26: 9.6M Q2 '26: 9.7M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q3 '24: -15.40 Q4 '24: 0.00 Q1 '25: 9.24 Q2 '25: 11.31 Q3 '25: 0.62 Q4 '25: 0.64 Q1 '26: -5.19 Q2 '26: -2.45 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.